As Jim mentioned the numbers posted by Astellas are the total for three quarters. Their info does not seem to break out the current quarters numbers. I find it odd that MDVN has not released at least an acknowledgment that Astellas has posted the number. Anyway if my math is right the current quarterly sales would be 130 million US and 25 million foreign vs 110 US and 9 foreign the previous quarter. Keep in mind these sales are shared so MDVN gets half the US and a smaller amount of the foreign. Analyst average estimates for the quarterly revenue was 72.69 million. That number looks to be pretty close. I believe many, including myself, were expecting an upside surprise. Hope my numbers are right, do your own diligence.
Quarterly numbers were $127 million vs $121 million consensus for US. Ex-US was $37M vs $21m consensus. MDVN never acknowledges the numbers posted by Astellas. Its fine though. Probably one of the best ideas in Biotech from this level.
If one has cancer and healthy insurance, he should go for the best medicine available at his time. With pre-chem, they should double their revenue without considering that factor, say for 70m to 140m, or 560m a year. But their CEO said in the last meeting that pre-cem is a much larger market, so one may have to double that number again without considering that factor. When one drug is better than the other, it usually means the spot they pick on the pathway is better than the other. That is a very exciting science.
A corner grocery earns more and out of this half, 10 % of the profits go directly to UCLA and Dr. Sawyers who invented Xtandi and is now working for the competition, JNJ, on the improved version nearly ready for approval.